Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
86.1 GBX | +0.82% | +8.29% | -2.71% |
07:35am | Marathon Partners Calls for Specifics of Dr. Martens' Cost-cutting, Buyback Plans | MT |
May. 20 | Marathon Partners Urges Dr. Martens to Buy Back Stock | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Footwear
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.71% | 1.04B | C+ | ||
+35.71% | 23.17B | B+ | ||
+30.85% | 11.11B | C+ | ||
+8.76% | 10.41B | C | ||
-2.32% | 9.02B | - | ||
+53.56% | 8.46B | B- | ||
-1.11% | 8.24B | A- | ||
+23.14% | 3.32B | A- | ||
+77.78% | 3.16B | B- | ||
-8.47% | 2.48B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DOCS Stock
- Ratings Dr. Martens plc